Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types

Takagi, Hidenori; Dong, Liang; Kuczler, Morgan D.; Lombardo, Kara; Hirai, Mitsuharu; Amend, Sarah R.; Pienta, Kenneth J.

doi:10.3390/ijms21239031

Cited by 10 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible for smaller MCCC's and many CTC's to be falsely binned as white blood cells, since the average cell diameters of CTC's fall within the 10 -15µm range. [35][36][37] A recent review also stated that microfluidic channel size can induce critical flow velocities resulting in shearing and disaggregation of CTC clusters. [18,38] Another review by Amintas et al concluded that individual CTC isolation techniques are typically not compatible with CTC cluster isolation.…”

Section: Current Tumor Cell Isolation Methods From Whole Bloodmentioning

confidence: 99%

Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study

Kouhmareh,

Martin,

Finlay

et al. 2023

Preprint

View full text Add to dashboard Cite

Metastasis remains the leading cause of cancer deaths worldwide. Lung cancer remains lethal, known for its highly metastatic progression. The unknown genomic profile of metastatic tumors coupled with their ability to selectively spread among different organs suggests more studies are needed to understand these different pathways. However, a bottleneck in metastatic cancer research is our insufficient understanding of these mechanisms, particularly how cancer cells are transported outside the primary tumor to specific distant metastatic sites. Unfortunately, access to the primary driver of malignancy, the metastatic cancer cell clusters (MCCCs), remains difficult and limited. These metastatic clusters have been shown to be 100-fold more tumorigenic than individual cancer cells. Capturing and characterizing MCCCs is a key limiting factor in efforts to help treat and ultimately prevent cancer metastasis. Understanding the biological pathways occurring within MCCCs will help uncover new therapeutic drug targets to help combat cancer metastases. We demonstrate a novel, proof of principle technology, to capture MCCCs directly from patients whole blood. Our tunable platform combines a biomimicry-based margination effect coupled with immunoaffinity to isolate MCCCs. Adopting a selective capture approach based on cancer cells overexpressing CD44 provides a methodology that preferentially isolates highly metastatic cells from whole blood. Furthermore, we demonstrate a high capture efficiency of 90% by isolating our model system MCCCs directly from whole blood. Characterization of the captured MCCCs from lung cancer patients by immunofluorescence staining and genomic analyses, reveals previously unseen potential drug targets that can unlock a new area of anti-metastatic therapeutics.

show abstract

Section: Current Tumor Cell Isolation Methods From Whole Bloodmentioning

confidence: 99%

Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study

Kouhmareh,

Martin,

Finlay

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The current that arose from redox cycling of pAP and its oxidized form, p-quinone imine (pQI), noticeably increased over time at a rate correlated to the expression level of the target cell surface antigen. Instead of capturing cells based on immunoaffinity, [62][63] or size, [64][65][66][67] we leveraged the dielectrophoretic properties of these cells for capture. These results are significant because they demonstrate the advantages of combining IDBPEs with DEP for multiple cell capture and analysis.…”

Section: Theoretical Backgroundmentioning

confidence: 99%

Dielectrophoretic Capture and Electrochemical Enzyme‐Linked Immunosorbent Assay of Single Melanoma Cells at an Array of Interlocked Spiral Bipolar Electrodes

Clark,

Moser,

Anand

2024

ChemElectroChem

View full text Add to dashboard Cite

Analysis of single cancer cells is critical to obtain accurate patient diagnosis and prognosis. In this work, we report the selective dielectrophoretic capture and electrochemical analysis of single melanoma cells at an array of interlocked spiral bipolar electrodes (iBPEs). Following dielectrophoretic capture, individual melanoma cells are hydrodynamically transferred into picoliter‐scale chambers for subsequent analysis. The interlocked spiral end of the iBPE (the sensing pole) is utilized to read out an electrochemical enzyme‐linked immunosorbent assay (eELISA), which quantifies the expression of a cell surface antigen, melanoma cell adhesion marker (MCAM). The opposite pole of each BPE is located in a fluidically isolated compartment containing reagents for electrogenerated chemiluminescence (ECL), such that luminescence reports iBPE current. In a preliminary device design, the ECL intensity was insufficient to detect MCAM expression on single cells. To achieve single‐cell analysis, we decreased the gap size between the interlocked spirals tenfold (5.0 μm to 0.5 μm), thereby creating a more sensitive biosensor by enhanced redox cycling of the product of eELISA. This work is significant because it allows for the selective isolation and sensitive analysis of individual melanoma cells in a device amenable to point‐of‐care (POC) application by combining dielectrophoresis (DEP) with interdigitated bipolar electrodes (IDBPEs).

show abstract

“…Recently, a study involving multiple cancer types, including RCC, compared two capture platforms: one based on the slit filter (CTC-FIND) and another based on free selection (AccuCyte ® -CyteFinder ® system) [69]. A significantly higher positive CTC rate (91.7%) was found using the CTC-FIND platform compared to the AccuCyte ® -CyteFinder ® system (66.7%).…”

Section: Membrane Filtrationmentioning

confidence: 99%

“…It was concluded that the CTC-FIND platform has a superior ability to capture positive CTCs, however of larger size. A warning was issued concerning the bias related to a higher preponderance of prostate cancer cases contributing to the results obtained and the small size of the sample used [69].…”

Section: Membrane Filtrationmentioning

confidence: 99%

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?

Couto-Cunha

Jerónimo

Henrique

2022

Cancers

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is among the 15 most common cancers worldwide, with rising incidence. In most cases, this is a silent disease until it reaches advance stages, demanding new effective biomarkers in all domains, from detection to post-therapy monitoring. Circulating tumor cells (CTC) have the potential to provide minimally invasive information to guide assessment of the disease’s aggressiveness and therapeutic strategy, representing a special pool of neoplastic cells which bear metastatic potential. In some tumor models, CTCs’ enumeration has been associated with prognosis, but there is a largely unexplored potential for clinical applicability encompassing screening, diagnosis, early detection of metastases, prognosis, response to therapy and monitoring. Nonetheless, lack of standardization and high cost hinder the translation into clinical practice. Thus, new methods for collection and analysis (genomic, proteomic, transcriptomic, epigenomic and metabolomic) are needed to ascertain the role of CTC as a RCC biomarker. Herein, we provide a critical overview of the most recently published data on the role and clinical potential of CTCs in RCC, addressing their biology and the molecular characterization of this remarkable set of tumor cells. Furthermore, we highlight the existing and emerging techniques for CTC enrichment and detection, exploring clinical applications in RCC. Notwithstanding the notable progress in recent years, the use of CTCs in a routine clinical scenario of RCC patients requires further research and technological development, enabling multimodal analysis to take advantage of the wealth of information they provide.

show abstract

Analysis of the Circulating Tumor Cell Capture Ability of a Slit Filter-Based Method in Comparison to a Selection-Free Method in Multiple Cancer Types

Cited by 10 publications

References 41 publications

Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study

Capture of circulating metastatic cancer cell clusters from a lung cancer patient can reveal a unique genomic profile and potential anti-metastatic molecular targets: A proof of concept study

Dielectrophoretic Capture and Electrochemical Enzyme‐Linked Immunosorbent Assay of Single Melanoma Cells at an Array of Interlocked Spiral Bipolar Electrodes

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?

Contact Info

Product

Resources

About